IL127851A0 - Inhibition of TNF activity - Google Patents

Inhibition of TNF activity

Info

Publication number
IL127851A0
IL127851A0 IL12785198A IL12785198A IL127851A0 IL 127851 A0 IL127851 A0 IL 127851A0 IL 12785198 A IL12785198 A IL 12785198A IL 12785198 A IL12785198 A IL 12785198A IL 127851 A0 IL127851 A0 IL 127851A0
Authority
IL
Israel
Prior art keywords
inhibition
derivative
heparin
tnf receptor
tnf activity
Prior art date
Application number
IL12785198A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Priority to IL12785198A priority Critical patent/IL127851A0/xx
Publication of IL127851A0 publication Critical patent/IL127851A0/xx
Priority to US09/623,225 priority patent/US6608044B1/en
Priority to JP2000591982A priority patent/JP2002534375A/ja
Priority to DK99961268T priority patent/DK1058544T3/da
Priority to PT99961268T priority patent/PT1058544E/pt
Priority to AT99961268T priority patent/ATE289506T1/de
Priority to EP99961268A priority patent/EP1058544B1/en
Priority to DE69923832T priority patent/DE69923832T2/de
Priority to AU17961/00A priority patent/AU780203B2/en
Priority to PCT/IL1999/000709 priority patent/WO2000040225A2/en
Priority to CA002322229A priority patent/CA2322229C/en
Priority to IL13802499A priority patent/IL138024A0/xx
Priority to ES99961268T priority patent/ES2237959T3/es
Priority to IL138024A priority patent/IL138024A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
IL12785198A 1998-12-30 1998-12-30 Inhibition of TNF activity IL127851A0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL12785198A IL127851A0 (en) 1998-12-30 1998-12-30 Inhibition of TNF activity
ES99961268T ES2237959T3 (es) 1998-12-30 1999-12-30 Inhibicion de la actividad del tnf con composiciones que comprenden heparina y receptores solubles del tnf.
EP99961268A EP1058544B1 (en) 1998-12-30 1999-12-30 Inhibition of tnf activity with compositions comprising heparin and soluble tnf recpetors
JP2000591982A JP2002534375A (ja) 1998-12-30 1999-12-30 活性阻害
DK99961268T DK1058544T3 (da) 1998-12-30 1999-12-30 Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer
PT99961268T PT1058544E (pt) 1998-12-30 1999-12-30 Inibicao da actividade do tnf
AT99961268T ATE289506T1 (de) 1998-12-30 1999-12-30 Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
US09/623,225 US6608044B1 (en) 1998-12-30 1999-12-30 Inhibition of TNF activity
DE69923832T DE69923832T2 (de) 1998-12-30 1999-12-30 Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
AU17961/00A AU780203B2 (en) 1998-12-30 1999-12-30 Inhibition of TNF activity
PCT/IL1999/000709 WO2000040225A2 (en) 1998-12-30 1999-12-30 Inhibition of tnf activity
CA002322229A CA2322229C (en) 1998-12-30 1999-12-30 Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
IL13802499A IL138024A0 (en) 1998-12-30 1999-12-30 Inhibition of tnf activity
IL138024A IL138024A (en) 1998-12-30 2000-08-23 Pharmaceuticals containing heparin to inhibit TNF activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12785198A IL127851A0 (en) 1998-12-30 1998-12-30 Inhibition of TNF activity

Publications (1)

Publication Number Publication Date
IL127851A0 true IL127851A0 (en) 1999-10-28

Family

ID=11072323

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12785198A IL127851A0 (en) 1998-12-30 1998-12-30 Inhibition of TNF activity
IL138024A IL138024A (en) 1998-12-30 2000-08-23 Pharmaceuticals containing heparin to inhibit TNF activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL138024A IL138024A (en) 1998-12-30 2000-08-23 Pharmaceuticals containing heparin to inhibit TNF activity

Country Status (12)

Country Link
US (1) US6608044B1 (xx)
EP (1) EP1058544B1 (xx)
JP (1) JP2002534375A (xx)
AT (1) ATE289506T1 (xx)
AU (1) AU780203B2 (xx)
CA (1) CA2322229C (xx)
DE (1) DE69923832T2 (xx)
DK (1) DK1058544T3 (xx)
ES (1) ES2237959T3 (xx)
IL (2) IL127851A0 (xx)
PT (1) PT1058544E (xx)
WO (1) WO2000040225A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
WO2002047696A1 (de) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
US7307361B1 (en) 2006-11-13 2007-12-11 Drs Power & Control Technologies, Inc. Medium voltage power converter formed using low voltage drives
US7576604B2 (en) * 2006-12-15 2009-08-18 Bin Xu All-digital class-D audio amplifier
EP2283045A1 (en) * 2008-05-20 2011-02-16 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
US8592557B2 (en) * 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
CZ232593A3 (en) * 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
KR100232688B1 (ko) * 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
WO1995003827A1 (en) * 1993-07-30 1995-02-09 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
DE4435612A1 (de) * 1994-10-05 1996-04-11 Braun Melsungen Ag Verfahren zur simultanen Entfernung von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus einer wäßrigen Flüssigkeit
AUPN673995A0 (en) * 1995-11-22 1995-12-14 Down Hole Technologies Pty Ltd A sleeve for orientating a tool
CA2301174C (en) * 1997-08-16 2007-11-27 Orthogen Gentechnologie Gmbh A method for inducing therapeutically-effective proteins

Also Published As

Publication number Publication date
CA2322229C (en) 2008-05-06
AU780203B2 (en) 2005-03-10
EP1058544B1 (en) 2005-02-23
AU1796100A (en) 2000-07-24
EP1058544A1 (en) 2000-12-13
ATE289506T1 (de) 2005-03-15
IL138024A (en) 2006-09-05
WO2000040225A3 (en) 2000-09-21
DE69923832T2 (de) 2005-12-29
DK1058544T3 (da) 2005-03-14
WO2000040225A2 (en) 2000-07-13
DE69923832D1 (de) 2005-03-31
JP2002534375A (ja) 2002-10-15
PT1058544E (pt) 2005-04-29
ES2237959T3 (es) 2005-08-01
CA2322229A1 (en) 2000-07-13
US6608044B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
MY115662A (en) Novel compounds with analgesic effect
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
CA2289717A1 (en) Novel therapy for constipation
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
MY119403A (en) Novel compounds with analgesic effect.
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
IL123889A0 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
HK51897A (en) Oral composition for the treatment of inflammatory bowel diseases
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
PL329802A1 (en) Derivatives of androstene
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
MA21264A1 (fr) Composition permettant d'administrer un medicament sous forme de gellules, d'une poudre ou d'un liquide.
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
ZA9110037B (en) The use of acetyl l-carnitine in the therapeutic treatment of coma and pharmacological compositions useful in such treatment
IL127851A0 (en) Inhibition of TNF activity
IL103294A0 (en) Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
IL126175A0 (en) Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same
WO2003045942A3 (en) Chemokine receptor antagonists and methods of use thereof
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
WO2001009119A3 (en) Chemokine receptor antagonists